Nanozyme-Based Strategies in Cancer Immunotherapy: Overcoming Resistance to Enhance Therapeutic Efficacy
Aging and Disease,
Год журнала:
2025,
Номер
unknown, С. 0 - 0
Опубликована: Янв. 1, 2025
Nanozymes,
which
are
nanomaterials
that
replicate
the
catalytic
activities
of
natural
enzymes
in
biological
systems,
have
recently
demonstrated
considerable
potential
improving
cancer
immunotherapy
by
altering
tumor
microenvironment.
Nanozyme-driven
immune
responses
represent
an
innovative
therapeutic
modality
with
high
effectiveness
and
minimal
side
effects.
These
nanozymes
activate
system
to
specifically
recognize
destroy
cells.
Combined
immunotherapeutic
agents,
can
amplify
anti-cancer
integrating
remodeling
immunogenic
cell
death
(ICD).
This
review
offers
a
thorough
discussion
about
various
involved
immunity,
including
those
mimicking
catalase
(CAT),
superoxide
dismutase
(SOD),
peroxidase
(POD),
oxidase
(OXD).
It
also
discusses
challenges
future
directions
for
translating
nanozyme
platforms
into
clinical
applications,
enhancing
susceptibility
cells
immunotherapy.
Nanozyme-based
strategies
substantial
oncology,
offering
new
effective
options
management.
Язык: Английский
Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy
Advanced Healthcare Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 24, 2025
Abstract
Poor
prognosis
and
chemotherapy
response
stem
from
difficulties
in
precise
targeting
the
lack
of
effective
synergistic
treatments.
Nanozymes
show
promising
potential
tumor
chemodynamic
therapy
(CDT)
by
catalyzing
hydrogen
peroxide
(H₂O₂)
decomposition
glutathione
depletion
microenvironment
(TME).
However,
integrating
with
CDT
remains
challenging.
In
this
study,
a
porous
Fe/Cu
bimetallic
nanozyme
carrier
(FeCuNPs)
is
developed
for
co‐loading
humanized
3F8
anti‐GD2
disialoganglioside
antibody
(3F8)
novel
pyridazinone‐based
chemotherapeutic
agent
(IMB),
forming
nanoreactor
(3F8@FeCuNPs@IMB)
targeted
CDT.
The
responds
specifically
to
acidic
TME
as
primary
insurance,
allowing
controlled
release
IMB
at
site.
coating
on
surface
acts
secondary
minimizing
drug
leakage
during
delivery
process
ensuring
chemotherapy.
Furthermore,
FeCuNPs
act
peroxidase‐like
(POD)
oxidase‐like
(GSHOX)
enzymes,
hydroxyl
radical
(•OH)
generation
depleting
excess
GSH,
enhancing
results
vitro
vivo
indicate
that
dual
insurance
designed
3F8@FeCuNPs@IMB
offers
prospect
targeted,
precise,
combination
against
melanoma.
Язык: Английский